购物车
- 全部删除
您的购物车当前为空
Anti-B7-1 Antibody-FITC (4I630)
还可以产品编号 TMAY-01080F
Anti-B7-1 Antibody-FITC (4I630) 是一种 FITC-conjugated Mouse 抗体，靶向 B7-1。Anti-B7-1 Antibody-FITC (4I630) 可用于 FCM。
Anti-B7-1 Antibody-FITC (4I630)
Anti-B7-1 Antibody-FITC (4I630)
还可以产品编号 TMAY-01080F
Anti-B7-1 Antibody-FITC (4I630) 是一种 FITC-conjugated Mouse 抗体，靶向 B7-1。Anti-B7-1 Antibody-FITC (4I630) 可用于 FCM。
产品信息正在更新中，如果您想购买，请点击大包装&定制按钮.
大包装 & 定制
联系我们获取更多批次信息
资源下载
产品介绍
生物活性
偶联与修饰
抗原信息
| 产品描述 | Anti-B7-1 Antibody-FITC (4I630) is a FITC-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-FITC (4I630) can be used in FCM. |
| Ig Type | Monoclonal Mouse IgG1 |
| 克隆号 | 4I630 |
| 交叉反应 | Human |
| 验证活性 | Profile of anti-B7-1 (CD80) reactivity on U937 cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with 20 μg of human IgG/106cells for 1 hour at 4 °C prior to staining, washed, then stained with FITC Mouse anti-B7-1 (CD80). |
| 应用 | FCM |
| 推荐剂量 | 10 μl/Test, 0.1 mg/ml |
| 抗体种类 | Monoclonal |
| 宿主来源 | Mouse |
| 构建方式 | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; TMPY-01063; NP_005182.1; Met 1-Asn 242) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| 纯化方式 | Protein A |
| 性状 | Liquid |
| 缓冲液 | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| 研究背景 | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| 偶联 | FITC |
| 其他可选修饰符 | Unconjugated/Biotin/PE |
| 可提供抗体种类 | 4 |
| 免疫原 | Recombinant Human CD80 / B7-1 Protein (TMPY-01063) |
| 抗原种属 | Human |
| 研究领域 | Cancer Drug Targets |
存储&运输
| 储存方式 | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| 运输方式 | Shipping with blue ice. |
SCI 文献
计算器
比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， 
评论列表
预览
Related Tags: buy Anti-B7-1 Antibody-FITC (4I630) | purchase Anti-B7-1 Antibody-FITC (4I630) | Anti-B7-1 Antibody-FITC (4I630) cost | order Anti-B7-1 Antibody-FITC (4I630)
嗨！有任何问题？点我咨询
评论内容